Understand the source comparison
Best Peptides for Restless Leg Syndrome: Mechanism Comparison
BPC-157 Anti-inflammatory, VEGF upregulation, dopamine D2 receptor modulation Indirect. Normalizes receptor expression in dopamine blockade models Subcutaneous injection (250–500 mcg daily) Preclinical only. Rodent catalepsy models, zero RLS trials Cerebrolysi
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- Anti-inflammatory, VEGF upregulation, dopamine D2 receptor modulation
- Indirect. Normalizes receptor expression in dopamine blockade models
- Subcutaneous injection (250–500 mcg daily)
- Preclinical only. Rodent catalepsy models, zero RLS trials
- Cerebrolysin
- Neurotrophic factor delivery (BDNF, NGF), anti-apoptotic signaling
- Indirect. Supports dopaminergic neuron survival under stress
- Intravenous infusion (30 mL daily × 10–20 days)
- Established in stroke/TBI; zero RLS-specific studies
- Dihexa
- HGF mimetic, synaptogenesis enhancement, c-Met receptor activation
- Indirect. Neuroprotection of dopamine neurons via HGF pathway
- Oral (5–10 mg daily)
- Preclinical cognitive models only; no human RLS data
- Thymalin
- Thymic peptide, immune modulation, cytokine regulation
- Minimal. Primarily immune-focused, unclear CNS dopamine effect
- Subcutaneous injection (10 mg every 3–5 days)
- Immune restoration contexts; RLS mechanism unclear
- MK-677
- Growth hormone secretagogue, IGF-1 elevation
- Minimal direct effect; sleep architecture improvement may reduce RLS severity
- Oral (10–25 mg nightly)
- Sleep quality studies exist; no RLS symptom trials